Carisma Therapeutics raised nearly $60M in Series A funding. Now what? - Technical.ly Philly

Business

Aug. 8, 2019 10:42 am

Carisma Therapeutics raised nearly $60M in Series A funding. Now what?

What's ahead for the cell therapy startup working out of the now-full BioLabs@CIC.
Lab space at BioLabs@CIC.

Lab space at BioLabs@CIC.

(Photo by Julie Zeglen)

Carisma Therapeutics, working on a cellular therapy aimed at fighting solid tumors, is planning for growth: The University City company is hoping to hire about 10 more employees by the end of the year after raising nearly $60 million, its CEO told Techncial.ly Philly.

The company, formerly known as CARMA Therapeutics, initially raised $53 million during its Series A round last year, partly through the University of Pennsylvania, although the institution didn’t share how much it contributed.

But Carisma picked up a few million more at the end of last year, CEO Steven Kelly said. The company extended its Series A, bringing in about $6 million more, led by AbbVie Ventures and HealthCap. The funding will be put toward “full research and development capabilities,” Kelly said, as well as hiring to reach about 30 employees total.

Carisma was the first to occupy space in the BioLabs@CIC shortly after it opened in December 2018 after previously working out of the Princeton BioLabs. It was touted as a darling of the lab space during a May reception at BioLabs@CIC, with Kelly providing some remarks about Philly’s attractiveness for growing a life sciences company (an opinion that falls in line with recent international recognition).

(Photo by Julie Zeglen)

Melina Blees speaks a BioLabs reception, May 2019.

Melina Blees, the site director of the BioLabs@CIC, said all lab spaces are now all occupied by biolife companies, alongside a healthy waiting list. Companies can choose either private or shared lab space.

Advertisement

“In many ways we’re competitive,” the Boston-bred Kelly told Technical.ly about working around other companies that are often striving for the same goals, “and in other ways we’re collaborative.”

The CEO said as the team grows, it will eventually look into getting its own space.

“For now, the facility is full. All the labs are taken,” he said. “That feels great as a biotech entrepreneur, to feel the energy around biotech and cell and gene therapy — that feels great.”

Blees agreed, saying that the space filling quickly with innovative companies has helped build the biotech and biolife community in Philly.

“It’s been really crazy, even faster than we anticipated,” she said. “It speaks to how the market is really ready for these offerings.”

-30-
CONTRIBUTE TO THE
JOURNALISM FUND

Already a contributor? Sign in here
Connect with companies from the Technical.ly community
New call-to-action

Advertisement

Relay Network just raised $30M. Here’s what its 2020 looks like

Village Capital’s Victoria Fram is the first guest on ‘Off the Sidelines,’ our new investor education podcast

10 life lessons I learned from Pete Musser

SPONSORED

Philly

Say ‘Ahoy’ to the technical opportunities at Vanguard

Philadelphia

Perpay

UX Designer

Apply Now

Chesterbrook, PA

Deacom

Inside Sales Representative

Apply Now

Horsham, PA

Penn Mutual

Product Owner/Business Transformation Specialist

Apply Now

Inside University City’s push to get those without four-year degrees into STEM careers

Philly tech remembers Safeguard Scientifics founder Pete Musser

3 words that describe these startup founders’ experiences raising VC

SPONSORED

Philly

Packed with growth opportunities, WSFS Bank moves into Philly

Center City

Inspire

Member Experience Specialist

Apply Now

Philadelphia, PA

Perpay

Frontend Engineer

Apply Now

Philadelphia, PA

Perpay

Relationship Marketer

Apply Now

Sign-up for daily news updates from Technical.ly Philadelphia

Do NOT follow this link or you will be banned from the site!